A new era of addiction treatment amplifies the stigma of disease and treatment for individuals with obesity.
MGH Weight Center, Department of Medicine- Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA.|Department of Medicine-Gastrointestinal Unit, Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, Boston, MA, USA.|Department of Medicine, Harvard Medical School Boston, Boston, MA, USA.
N
N
Alfaris
ConscienHealth, Pittsburgh, PA, USA.|Obesity Action Coalition, Tampa, FL, USA.
T K
TK
Kyle
MGH Weight Center, Department of Medicine- Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA.|Department of Medicine, Harvard Medical School Boston, Boston, MA, USA.
J
J
Nadai
MGH Weight Center, Department of Medicine- Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA.|Department of Medicine, Harvard Medical School Boston, Boston, MA, USA.|Department of Pediatrics Endocrinology, Massachusetts General Hospital, Boston, MA, USA.
F C
FC
Stanford
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D016739:Behavior, Addictive / Q000188:drug therapy* / Q000523:psychology; D016642:Bupropion / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy* / Q000523:psychology; D010353:Patient Education as Topic; D057545:Social Stigma; D013240:Stereotyping; D014481:United States
D019440:Anti-Obesity Agents; D016642:Bupropion; D009271:Naltrexone